Emily C. Weiss-Cook is an associate in the corporate department in New York. She advises issuers, underwriters and investors on a variety of capital markets matters, including IPOs and follow on equity offerings, investment-grade debt offerings and convertible and exchangeable notes transactions. She advises clients on transactions spanning a broad array of industries, including life sciences, financial services, public utilities and industrials. Emily also counsels public companies in connection with public reporting, SEC and stock exchange compliance and corporate governance matters, including shareholder activism.
Prior to joining the firm in 2022, Emily was a corporate associate in the New York office of a premier U.S. law firm, where she advised clients on capital markets, banking and finance, mergers & acquisitions and general corporate matters.
Experience
Examples of representative matters include:
- Represented Zenas BioPharma, Inc. in its $225 million initial public offering, its $120 million PIPE offering, its $200 million ATM offering and its concurrent $200 million convertible notes and $100 million common stock offerings.
- Represented Spyre Therapeutics, Inc. in multiple follow-on offerings of common stock totaling more than $750 million.
- Represented the underwriters in Arxis, Inc.’s $1.3 billion initial public offering.
- Represented Xenon Pharmaceuticals, Inc. in its $747 million follow on offering of common stock and pre-funded warrants.
- Represented LPL Holdings, Inc. in multiple investment grade bond offerings totaling $1.75 billion.
- Represented the underwriters in follow-on offerings of common stock by Biohaven Ltd. totaling more than $700 million.
- Represented Foghorn Therapeutics, Inc. in multiple registered direct offering of shares of common stock and pre-funded warrants totaling $160 million.
- Represented Eversource Energy and its subsidiaries through more than $7.4 billion in debt offerings and other capital markets transactions.
- Represented LifeStance Health in multiple secondary offering by certain selling stockholders.
- Represented Acushnet Holdings Corp., in its $500 million Rule 144A / Regulation S debt offering.
- Represented Alnylam Pharmaceuticals, Inc. in its Rule 144A convertible notes offering.
- Represented Sarepta Therapeutics, Inc. in multiple exchanges of over $900 million of convertible notes for a combination of new convertible notes, common stock and cash.
- Represented Servpro Industries, LLC, a portfolio company of The Blackstone Group Inc., in a $500 million whole-business securitization financing.
- Represented the underwriters in numerous notes offerings for Blackstone Private Credit Fund totaling $1 billion.
- Represented the underwriters in a follow-on offering for Blackstone Secured Lending Fund totaling approximately $175 million.
- Represented TravelCenters of America in its acquisition by BP.
- Represented Radius Health in its acquisition by Gurnet Point and Patient Square.
- Represented Northrop Grumman Corporation in connection with its offer to exchange new unsecured notes for up to approximately $1.2 billion of existing notes.*
- Represented the underwriter in connection with the $200 million initial public offering of units of World Quantum Growth Acquisition Corp., a special purpose acquisition company.*
- Represented Crown Castle International Corp. in connection with its $750 million registered senior notes offering.*
- Represented the underwriters in connection with the $1.5 billion registered senior notes offering of Skyworks Solutions, Inc.*
- Represented the initial purchasers in connection with the $500 million 144A/Reg. S high-yield senior secured notes offering of WW International, Inc.*
- Represented the initial purchasers in connection with the $300 million 144A/Reg. S high-yield senior secured second-lien notes offering of Arconic Corporation.*
- Represented the underwriters in connection with the $2.2 billion registered high-yield senior notes offering of Centene Corporation.*
*Experience prior to joining Ropes & Gray